Panacea Venture

Founder and Managing Partner James Huang leads the investment strategy. Huang brings over 30 years of biotech experience, spanning roles at Kleiner Perkins, Vivo Ventures, and as president of Anesiva. Investment execution is supported by a 24-person team that includes partners with deep operational backgrounds in pharma, regulatory affairs, and clinical development.

Panacea leans on a cross-border network that spans three continents, with particular density in China and the U.S. The firm’s “business development first” model places ex-pharma dealmakers alongside investment partners, giving it direct line-of-sight into licensing discussions and corporate carve-outs that never reach a broad auction process.

Panacea executes direct investments in private and public companies. There is no public indication that the firm commits capital to other managers as a fund-of-funds. Its public-company program functions as a structured direct strategy rather than a separate hedge fund allocation.

The firm covers the full company lifecycle, from seed-stage company formation through expansion, late-stage crossover, and public-company investing. The flexibility is deliberate: Panacea describes an asset-centric approach that follows a drug program through regulatory milestones regardless of the corporate wrapper.

Panacea is a direct spinout. James Huang was Managing Partner of Kleiner Perkins China before leaving in 2017 to found Panacea, taking several team members with him. There is no disclosed ongoing economic or strategic relationship between the two firms.